Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This really needs news of pivotal trials starting I believe that will drive volume in this. That or the final prostate cancer data.
To me I still find it skeptical that this company has refused to uplist to the NASDAQ where SEC requirements for financials are more strict. That's why lots of companies trade on OTC they have more leniency when it comes to having to disclose financials.
3rd line pancreatic cancer phase 2 pivotal is going to start Q3
2nd line pancreatic cancer phase 2 pivotal Precision Promise is going to start Q3. The goal with Precision Promise is to start
A.)monotherapy SM-88 first in 2nd line PC patients
B.) then SM-88/chemo combo for 1st line PC patients soon after 2nd line starts
Q3 of 2019 is July - September of 2019. That means these pivotal studies are intended to be started between these months, pending there is no type of delay.
Final prostate cancer phase 2 data is expected 2nd half of 2019
Update On TYME-18 IND expected 2nd half of 2019
Preclinical data using SM-88 for 15 cancer types expected 2nd half of 2019.
THe reason why it didnt' is because there was no disclosure of upfront money or costs. The main events would be the initiations of the 2 upcoming pivotal studies starting. I think these events will drive volume. Then the prostate cancer data should also. Then the preclinical data for 15 cancers.
Definitely being manipulated on low volume, load up big time on TYME.
Highly positive news for TYME
https://finance.yahoo.com/news/tyme-technologies-announces-collaboration-nyu-120000429.html
yah but look at the source, it's his Ex. An Ex with an axe to grind so to say could always make up any lie just to smear him. Not defending RP if he did wrongdoing, but just a tidbit of info.
What a disaster this has been, honestly the CEO Nader sucks.
1,) postponed timelines always changing, which is understandable based on FDA but just outright wrong projections.
2,) still, no uplist. to me it's fishy why the CEO doesn't want to push onto the NASDAQ or uplist at all. I believe it's because the financials are shady and can be done so while on the OTC. if they hit the NASDAQ they have stricter reporting requirements.
3,) I think CYDY Pro-140 technology is awesome but Cytodyn needs a new CEO and management to carry it forward. So many terrible missteps by this CEO. I used to believe Nader and was always bullish but things only get worse from him.
I hope everyone invested in CYDY makes money and I hope it pans out, but Nader needs to step down IMO. Get a new CEO that has a better vision.
I posted this elsewhere but I thought I would share why I am heavily invested in Tyme Technologies:
yes hi I am new. I have been posting the catalysts coming in 2nd half of 2019. About the phase 3 studies I can't believe that investors aren't buying. That's because both the 3rd line from the company, and the 2nd line from PanCAN are allowed to be set up as pivotal according to the FDA. That means with good data Tyme will gain accelerated approval for each study they won't need a phase 3 for approval. I did my DD and I liked everything about the biotech.
For instance)
1.) multiple catalysts in 2nd half of 2019 as I posted in other post, there are about 5 catalysts approaching at any moment in 2019
2,) The CEO and co-founder both each own about 2.64 million shares, which I found refreshing because many biotechs the CEO or insiders never buy or own any shares. It's encouraging that insiders own that many shares it makes me believe that they have confidence in their product.
3,) I liked the way they treat cancer by removing the musin layer that protects it using modified tyrosine and oxidative stress. The science to me is intriguing. By removing the musin layer the cancer cell is exposed and it's defense at that point is weak. Best part of all is that healthy cells in humans don't take up such amino acids like tyrosine, therefore, healthy cells are not affected. That's why there is barely any adverse events in all the studies observed to date.
4,) They are diversifying the pipeline by gearing up TYME-18 for intratumoral injection and then they have other products.
5,) They have already developed proof of concept in prostate cancer and pancreatic cancer. If it was just pancreatic cancer alone then I might be cautious, but since they already shown impressive data in two types of cancer it leads me to believe SM-88 works in treating multiple types of cancer and it has efficacy.
yes just needs volume, but with 5 catalysts I'm sure volume will definitely come. Just need people to stop selling for pennies though.
Doesn't matter, low volume. volume has only reached 150,000 the whole day just about.
There are 5 catalysts approaching in 2nd half of 2019. Once the volume comes it will be different for TYME
Multiple catalysts on the way in 2nd half of 2019,
Two pivotal trial initiations for pancreatic cancer - 2nd line and 3rd line respectively.
Preclinical data from 15 types of cancer using SM-88
Final Prostate cancer data expected
IND to begin studying TYME-18 product for intratumoral injection
So many irons in the fire, TYME still way undervalued with a low market cap
Yes I'm shocked I found this at such a low price. Their drug has proven proof of concept in 3rd line pancreatic cancer and prostate cancer. I like the unique science also no other biotech has metabolism of cancer. Adverse events aren't bad either only 4% of patients had grade 3 or higher adverse events.
Good move today, I hope to see a continuation for TYME on Thursday also.
Multiple catalysts are expected here in the 2nd half of 2019, what's not to like about TYME. I can't believe this biotech is only trading at $1.17 per share.
1.) Preclincial data of SM-88 in multiple types of cancer
2.) Initiation of PanCan Precision pivotal study for 2nd line pancreatic cancer
3,) Initiation for 3rd line pivotal pancreatic cancer trial
4,) full results from phase 2 prostate cancer study
around $1.18 per share for TYME
I agree with you. Tyme Technologies is way undervalued. Especially with proof of concept already in prostate cancer and pancreatic cancer.
Correct, Marker should have a much larger market cap at least $1 billion + now. Proven successful already in multiple types of blood cancer and now in solid tumors. I will just be patient and hold long-term as I think in the future this gets a partnership or bought out at some point.
Matter of fact all the questions were from brokerages, I didn't see any individual investor questions asked.
That's possible to do yes. I agree with you on that.
Are you talking about Arm A? Because as of the latest update according to the press release there are 7 out of 9 patients still alive. you can check it out in the PR.
That is correct, after 3 months chemo no longer works and the tumor grows/patient plateaus.
Okay let me be more specific, after 3 months patients plateau and drop off the chart. The first 3 months on chemo they are stable and then after 3 months of chemo, if you look at a chart they drop off a cliff.
It's possible we get new commentary from analysts, my guess is Monday morning. My guess is likely after the conference call in the morning with Marker.
I could see the FDA being lenient possibly and allowing the phase 1/2 study to complete. Remember, they only showed the evaluable patients enrolled initially. The FDA might state to allow this trial to finish treating the rest of the patients and then depending upon data possibly gain conditional approval. That's my opinion. The FDA is a mixed bag so nobody knows 100% what it wants.
Here is the bottom line for ARM A that you need to know. Patients who would otherwise die in 3 months - 7 of 9 are still alive today many months later. Don't look that much into it. The therapy works, MultiTAA does its job.
What they did is they led in patients with 3 months of chemotherapy, because after the 3rd month they always plateau.
However, after 3 months patients were given combination chemo along with MultiTAA and that kept patients alive longer. As you see, they stated in the PR 7 out of 9 patients are still alive today as of last update.
Marker could release the abstract in a press release (limited information), but the full clinical data released today they couldn't reveal until the time of the conference/presentation.
"Abstracts selected for the official AACR Annual Meeting press program are embargoed until date and time of presentation, either at an official AACR press conference or in a scientific session"
https://www.aacr.org/Newsroom/Pages/embargo-policy.aspx
This is the last time I will post this. You can ignore facts if you want but it doesn't change them.
Here you go:
https://www.aacr.org/Newsroom/Pages/embargo-policy.aspx
"Abstracts selected for the official AACR Annual Meeting press program are embargoed until date and time of presentation, either at an official AACR press conference or in a scientific session. Press program abstracts will be made publicly available once the embargo lifts. Public information officers or public relations firms representing academia or industry with abstracts in the official press program should work closely with the AACR Communications and Public Relations Department to coordinate publicity efforts and ensure that embargo and outside press material policies are followed."
They had to wait till data was presented first at the conference and release it at the same time. They were embargoed from releasing it early please educate a bit first.
In ARM A 7 out of 9 evaluable patients remain alive today above historical norm after MultiTAA treatment. Who sold on Friday seriously? Highly manipulated share price. Whoever bought you are very smart, whoever sold well you have no clue about biotech at all.
It's protective language. They can't say with certainty as the product hasn't passed a phase 3 study yet with a placebo control. So they have to say possibly a game changer or possibly a cure.
Because there was no PR, no conference call, no presentation done yet at AACR until Saturday July 20, 2019. This information got leaked from Healios which published it. But since no PR from company or CC they couldn't get a chance to explain the data.
The situation is different on Monday, because there will be a presenation done at AACR 2019 over the weekend, a CC in the morning at 8:30 a.m. est time and possibly a PR.
Hanscott that's the smartest thing I have read on this board today. Thank you. You are correct, in that traders/investors were expecting a complete 100% cure rate. This is not breast cancer, lung cancer, bladder cancer, prostate cancer, kidney cancer, this is pancreatic cancer.
Pancreatic cancer has always been the hardest to treat since the beginning of time. Heck seeing patients go 1 to 6 months on SD without advancing is a miracle in itself. Life expectancy for PC is 2 to 3 months. If SD can happen and extend life for 6 to 8 months or more that would be another game changing finding.
6 patients in ARM B had chemo-refractory pancreatic cancer. Meaning, chemotherapy did absolutely squat for these 6 patients. When MultiTAA given 3 patients had stable disease ranging from 1 month to 6 months, the other 3 progressed. This is a type of cancer that has an overall survival rate of 2-3 months. I think you sir are totally wrong. Prove me wrong?
Low volume, manipulation on a Friday, options expiration, short sellers, traders flipping out for pennies, and no CC/PR today. I think once the CC and PR comes Monday things will turn around fast for Marker. Just gotta be patient in these types of biotechs.
Back over 7+ On Monday with CC and probably a Press release also. Totally manipulated today. You are talking about a population pancreatic cancer that has life expectancy of 2 to 3 months on chemotherapy. marker's treatment has already shown stable disease for longer. This is a no brainer easily higher on Monday and Tuesday.
To add also possibly short-sellers covering. Unless they really want to go into the weekend without covering. I expect some type of a short-squeeze being possible tomorrow for MRKR. Cause it will be too late to trade anything on Monday. Stock will either be very high or lower. Good luck to all us shareholders.